← All trials
NCT06611163
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2024
- Primary completion
- Dec 31, 2025
- Completion date
- Jan 31, 2027
- First posted
- Sep 24, 2024
- Last posted
- Oct 8, 2024
- Enrollment
- 192
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sun PharmaceuticalsLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.